- Home
- THC vs WAT Comparison
THC vs WAT Comparison
Compare THC & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THC
- WAT
- Stock Information
- Founded
- THC 1967
- WAT 1958
- Country
- THC United States
- WAT United States
- Employees
- THC N/A
- WAT N/A
- Industry
- THC Hospital/Nursing Management
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- THC Health Care
- WAT Industrials
- Exchange
- THC Nasdaq
- WAT Nasdaq
- Market Cap
- THC 17.7B
- WAT 17.4B
- IPO Year
- THC N/A
- WAT 1995
- Fundamental
- Price
- THC $194.16
- WAT $378.00
- Analyst Decision
- THC Buy
- WAT Buy
- Analyst Count
- THC 19
- WAT 13
- Target Price
- THC $217.89
- WAT $379.00
- AVG Volume (30 Days)
- THC 1.1M
- WAT 657.2K
- Earning Date
- THC 10-28-2025
- WAT 11-04-2025
- Dividend Yield
- THC N/A
- WAT N/A
- EPS Growth
- THC N/A
- WAT 3.82
- EPS
- THC 14.57
- WAT 10.88
- Revenue
- THC $20,846,000,000.00
- WAT $3,105,638,000.00
- Revenue This Year
- THC $3.67
- WAT $7.12
- Revenue Next Year
- THC $4.52
- WAT $6.22
- P/E Ratio
- THC $13.36
- WAT $34.80
- Revenue Growth
- THC N/A
- WAT 6.90
- 52 Week Low
- THC $109.82
- WAT $275.05
- 52 Week High
- THC $217.43
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- THC 42.80
- WAT 74.17
- Support Level
- THC $198.33
- WAT $340.09
- Resistance Level
- THC $210.34
- WAT $382.02
- Average True Range (ATR)
- THC 7.65
- WAT 10.45
- MACD
- THC -1.30
- WAT 1.74
- Stochastic Oscillator
- THC 20.20
- WAT 92.26
About THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.